Kiadis to present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
24 Novembro 2020 - 3:00AM
Amsterdam, The Netherlands, November 24,
2020 – Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext
Amsterdam and Brussels: KDS), a clinical-stage
biopharmaceutical company developing innovative NK-cell-based
medicines for the treatment of life-threatening diseases, today
announces that Kiadis will participate in the 2020 Piper Sandler
32nd Annual Virtual Healthcare Conference. Arthur Lahr, the
company’s chief executive officer, will participate in a fireside
chat and host one-on-one meetings with investors on Thursday,
December 3, 2020.
A recording of the fireside chat may be accessed
by visiting the "For Investors" section of the Company's website
under the "Events and Presentations". A replay of the fireside chat
will be available for 90 days.
Dutch Translation/Nederlandse vertaling
Kiadis Pharma N.V. (‘Kiadis’),
een biofarmaceutisch bedrijf in de klinische fase dat innovatieve
op NK-cellen gebaseerde geneesmiddelen ontwikkelt voor de
behandeling van levensbedreigende ziekten, maakt bekend dat het zal
deelnemen aan de virtuele 32e Piper Sandler Health Conference. CEO
Arthur Lahr zal op donderdag 3 december 2020 deelnemen aan een
zogeheten ‘fireside chat’ en één-op-één meetings hebben met
investeerders.
Een video-opname van de chat kan worden bekeken
door naar het gedeelte "For Investors" te gaan op de Kiadis-website
onder het tabblad "Events and Presentations". Een replay van de
fireside chat blijft 90 dagen beschikbaar.
Dit persbericht vormt een samenvatting
van het gepubliceerde Engelstalige persbericht. Bij eventuele
verschillen is de tekst van het Engelstalige persbericht altijd
leidend.
Contacts
Kiadis: Maryann
Cimino, Sr. Manager, Corporate Affairs Tel: +1 (617) 710-7305
m.cimino@kiadis.com |
LifeSpring Life Sciences
Communication:Leon Melens (Amsterdam)Tel: +31 538 16
427lmelens@lifespring.nl Optimum Strategic
Communications: Mary Clark, Supriya Mathur Tel: +44 203
950 9144 kiadis@optimumcomms.com |
About KiadisFounded in 1997,
Kiadis is building a fully integrated biopharmaceutical company
committed to developing innovative cell-based medicines for
patients with life-threatening diseases. With headquarters in
Amsterdam, The Netherlands, and offices and activities across the
United States, Kiadis is reimagining medicine by leveraging the
natural strengths of humanity and our collective immune system to
source the best cells for life.
Kiadis is listed on the regulated market of
Euronext Amsterdam and Euronext Brussels since July 2, 2015, under
the symbol KDS. Learn more at www.kiadis.com.
Forward Looking Statements
Certain statements, beliefs and opinions in this press release are
forward-looking, which reflect Kiadis' or, as appropriate, Kiadis'
officers' current expectations and projections about future events.
By their nature, forward-looking statements involve a number of
known and unknown risks, uncertainties and assumptions that could
cause actual results, performance, achievements or events to differ
materially from those expressed, anticipated or implied by the
forward-looking statements. These risks, uncertainties and
assumptions could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
regulation, competition and technology, can cause actual events,
performance, achievements or results to differ significantly from
any anticipated or implied development. Forward-looking statements
contained in this press release regarding past trends or activities
should not be taken as a representation that such trends or
activities will continue in the future. As a result, Kiadis
expressly disclaims any obligation or undertaking to release any
update or revisions to any forward-looking statements in this press
release as a result of any change in expectations or projections,
or any change in events, conditions, assumptions or circumstances
on which these forward-looking statements are based. Neither Kiadis
nor its advisers or representatives nor any of its subsidiary
undertakings or any such person's officers or employees guarantees
that the assumptions underlying such forward-looking statements are
free from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the anticipated or
implied developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.